COMT genotypes and use of antipsychotic medication: Linking population-based prescription database to the HUNT study

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 4, 2008, Pages 372-377

  Hagen, Knut ^a,b   Stovner, Lars Jacob ^a,b   Skorpen, Frank ^a   Pettersen, Elin ^a   Zwart, John Anker ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antipsychotic medication; Epidemiology; Norway; Polymorphism; Prescription

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; NEUROLEPTIC AGENT; VALINE; DIPEPTIDE; METHIONYLMETHIONINE; UNCLASSIFIED DRUG; VALYLVALINE;

ADULT; ALLELE; ARTICLE; CODON; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; DOSE RESPONSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; NORWAY; PHARMACOGENETICS; POPULATION GENETICS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; FACTUAL DATABASE; GENETIC POLYMORPHISM; GENETICS; METHODOLOGY; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; DATABASES, FACTUAL; DIPEPTIDES; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NORWAY; POLYMORPHISM, GENETIC;

EID: 42149089334     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1567     Document Type: Article

References (22)

1. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
2. Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
3. Lachman HM, Nolan KA, Mohr P, et al. Association between catechol-O-imethyltransferase genotype and violence in schizophrenia and schizoaffective disorders. Am J Psychiatry 1998; 155: 835-837.
4. Nolan KA, Volavka J, Czobor P, et al. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatr Genet 2000; 10: 117-124.
5. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003; 160: 469-476.
6. Funke B, Malhotra AK, Finn CT, et al. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct 2005; 1: 19.
7. Massat I, Souery D, Del-Favero J, et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry 2005; 10: 598-605.
8. Woo JM, Yoon KS, Yu BH. Catechol-O-methyltransferase genetic polymorphism in panic disorder. Am J Psychiatry 2002; 159: 1785-1787.
9. Azzam A, Mathews CA. Meta-analysis of the association between the catechol-O-methyltransferase gene and obsessive-compulsive disorders. Am J Med Genet 2003; 123: 64-69.
10. Illi A, Mattila KM, Kampman O, et al. Catecho-l-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J Clin Psychopharmacol 2003; 23: 429-434.
11. Inada T, Nakamura A, Iijima Y. Relationship between catecho-l-O-methyltransferase polymorphism and treatment-resistant chizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 120: 35-39.
12. Holmen J, Midthjell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995-97(HUNT 2): objectives, contents, methods and participation. Nor J Epidemiol 2003; 13: 19-32.
13. Happonen P, Voutilainen S, Tuomainen TP, et al. Catecho-l-O-methyltransferase gene polymorphism modifies the effect of coffee intake on incidence of acute coronary events. PLoS ON 2006; 1: e117.
14. Hagen K, Stovner LJ, Skorpen F, et al. The impact of Val/Met polymorhisms in the catechol-O-methyltransferase gene on survival in the general population. The HUNT study. BMC Med Genet 2007; 8: e34.
15. Hagen K, Stovner LJ, Pettersen E, et al. High systolic blood pressure is associated with Val/Val genotype in the catecho-l-O-methyltransferase gene. The HUNT Study.Am J Hypertens 2007; 20: 21-26.
16. Szegedi A, Rujescu D, Tadic A,et al. The catecho-l-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.Pharmacogenomics J 2005;5: 49-53.
17. Nolan KA, Czobor P, Chrome LL, et al. Catechol-O-methyltransferase and monoamine oxidase-A-polymorphisms and treatment response to typical and atypical neuroleptics. J Clin Psychopharmacol 2006;26: 338-339.
18. Illi A, Kampman O Hänninen K, et al. Catecho-l-O-methyltransferase Val108/158Met genotype and response to antipsychotic medication in schizoohrenia. Hum Psychopharmacol Clin Exp 2007; 22: 211-215.
19. Bertolino A, Caforio G, Blasi G, et al. InterATCion of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798-1805.
20. Woodward ND, Jayathilake K, Melzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007; 90: 86-96.
21. Mata I, Arranz MJ, Staddon S, et al. The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr Genet 2006; 16: 213-216.
22. Weinshilboum RM. Pharmacogenornics: catechol-O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol 2006; 26: 539-561.